The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound and (b) a compound which modulates the JAK2-STAT5 pathway for the treatment of a proliferative disease, especially a solid tumor disease； a pharmaceutical composition comprising such a combination； the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease； a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use； and to a method of treatment of a warm-blooded animal, especially a human.
